NAD+ Research Nucleotide

Yes. Every batch of NAD+ is tested by an independent third-party laboratory using HPLC and MS-UPLC, confirming purity and mass identity before the batch is released. Pure Peptides does not test its own material.

It means NAD+ is supplied for in-vitro laboratory research and for no other purpose, and must not be administered to humans or animals. NAD+ is legal to purchase in the United States for in vitro and non-clinical laboratory research. It has no FDA approval. Outside the United States, NAD+ is the active ingredient of an approved injectable medicine. The material supplied here is a research-grade preparation, is not that medicine, and holds no marketing authorization. As a laboratory-grade nucleotide, NAD+ carries no scheduling restrictions under the Controlled Substances Act. Sold strictly for qualified research use, not human or veterinary administration.

NAD+ ships from US stock with cold-chain packaging and full tracking; orders placed before noon EST on business days are typically dispatched the same business day. On arrival, store the lyophilized powder at -20°C or below, dry and protected from light.

No. Nicotinamide riboside and nicotinamide mononucleotide are smaller precursor molecules that cells convert into NAD+. They are different substances from NAD+, and most published human work uses one of them rather than NAD+ itself. When comparing published results, check which molecule was actually given. The NAD+ research article keeps the studies that gave NAD+ itself apart from the precursor trials for this reason.

The NAD+ research article located three human studies of NAD+ itself, all of which gave it by intravenous infusion. The first was a pharmacokinetic pilot in eleven men, eight of whom received a six-hour infusion, with plasma and urine sampled throughout. Neither NAD+ nor its metabolites rose in plasma until after two hours. The authors concluded that at the rate used, NAD+ was rapidly and completely removed from the plasma for at least the first two hours, and that the metabolite pattern was consistent with the molecule being broken apart. A single-center randomized placebo-controlled trial in 180 adults with heart failure from ischemic cardiomyopathy met its primary endpoint, ejection fraction at one month, at 45.44% against 42.44% on placebo; its clinical secondary endpoints showed only non-significant trends. A retrospective record review at a commercial wellness provider compared intravenous NAD+ with intravenous nicotinamide riboside and reported moderate to severe gastrointestinal symptoms, increased heart rate and chest pressure during the NAD+ infusions, all of which resolved when the infusions ended.